




CE Registration No.:DE/CA09/0170/D01/IVD/016-03 CFDA Registration No: 20203400063


double targets labeled

endogenous internal standard control



Intended for use of 2019 Novel Coronavirus RNA Detection kit

CORONAVIRUS



*In order to better stop the epidemic situation of 2019 Novel Coronavirus wide spreading, DAAN GENE company developed the 2019-nCoV RNA detection kit, aiming to supply timely and effective detection service to extensive medical organizations.

*This kit can detect ORF1ab and N gene simultaneously, endogenous internal standard can monitor the experiment from sampling process, assess the sampling qualified or not(exogenous internal standard do not have this advantage), and monitor the occurrence of false negative effectively, assisting early clinical diagnostic, early treatment.

Product information

- *Intended for use: in vitro qualitative RNA detection of 2019-nCoV.
- *Package spec: 24 tests/kit, 48 tests/kit, 96 tests/kit.
- *Main components: PCR reaction solution, negative & positive controls, internal standard, etc.
- *Applicable instruments: ABI 7500, LightCycler 480, AGS4800, etc.
- *Applicable sample: throat swabs, bronchoalveolar lavage fluid(BALF) and sputum.

Product Characteristics	Performance
Validity period	-20±5°C, 6 months
Amplification sample volume	5μl
Detection sensitivity	LOD: 500 copies/ml
Detection precision	CV<5%
Cross reaction	No cross reaction with other pathogens of the same infection site or similar infection symptom.